Ligand-Mediated Targeting: An Update

@article{Allen2004LigandMediatedTA,
  title={Ligand-Mediated Targeting: An Update},
  author={Theresa M. Allen},
  journal={2004 International Conference on MEMS, NANO and Smart Systems (ICMENS'04)},
  year={2004},
  pages={611-612}
}
Several antibody therapeutics have received clinical approval and, in clinical trials for the treatment of cancer, they have been shown to have additive or synergistic effects with conventional anticancer drug therapy. Ligand-targeted therapeutics have received considerable attention in recent years (1) and several ligand-targeted therapeutics have received clinical approval (Table 1) Many nanoparticle delivery systems for anticancer drugs (primarily liposomal to date) have also entered the… CONTINUE READING

Tables and Topics from this paper.

Explore Further: Topics Discussed in This Paper

Citations

Publications citing this paper.

References

Publications referenced by this paper.
SHOWING 1-10 OF 11 REFERENCES

Ligand-targeted liposomal anticancer drugs.

  • Progress in lipid research
  • 2003
VIEW 1 EXCERPT

Targeted delivery and antitumour effects of c-myc antisense oligodeoxynucleotides in human melanoma cells mediated by anti-GD2immunoliposomes

F. Pastorino, C. Brignole, +7 authors M. Ponzoni
  • Clin. Cancer Res. in press,
  • 2003
VIEW 1 EXCERPT